NSESpurt in Volume3d ago · 11 Nov 2026, 11:22 am
Spurt in Volume
Sun Pharma Advanced Research Company Limited · SPARC
✦ AI SummaryRegulatory
Sun Pharma Advanced Research Company Limited has responded to the National Stock Exchange of India Ltd. (NSE) regarding a significant increase in volume, confirming compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and stating that all required disclosures have been made to the exchanges.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk8/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Significant increase in volume has been observed in Sun Pharma Advanced Research Company Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Sun Pharma Advanced Research Company Limited has submitted their response.
Attachments (1)
📄pdf
Download →
SPARC_11112026112221_ClarificationregardongincreaseinVolume11112026.pdf
View document text
SPARC/Sec/SE/2026-27/49 November 11, 2026
The National Stock Exchange of India Ltd. (NSE),
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.
Scrip Symbol – SPARC
Sub: Clarification – Increase in Volume
Ref: Email dated November 09, 2026
Dear Sir/Madam,
With reference to above referred communication, we confirm that the Company is in compliance
with the requirements of Regulation 30 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015 and that all the disclosures required to be made under the said
regulation have been made to the exchanges. We are not aware of any information which qualifies
to be disclosed under the said regulation but have not been disclosed.
We remain committed to make adequate and timely disclosures to the Stock Exchanges in
compliance with the applicable regulations.
We request you to kindly take the same on record.
Yours sincerely,
For Sun Pharma Advanced Research Company Limited
Kajal Damania
Company Secretary and Compliance Officer